Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplant G3 capsules
- Development stage
- Phase 2
- Lead developer
- Boston Medical Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplant G3 is an oral, frozen capsule formulation of fecal microbiota transplant (FMT) developed by Boston Medical Center. It is designed to restore gut microbiome diversity and prevent recurrence in patients following a first episode of *Clostridium difficile* infection (CDI). The 'G3' (third generation) formulation is specifically designed to deliver the microbial product to the large intestine, offering a non-invasive alternative to traditional colonoscopic or endoscopic delivery methods. By replenishing the commensal gut flora, the therapy aims to reverse the dysbiosis caused by the infection and subsequent antibiotic treatments, such as vancomycin, thereby reducing the risk of disease relapse.
- Other names
- Oral FMT capsulesFrozen oral FMT capsulesFecal microbiota transplant G3-Boston Medical Center-Clostridium difficile infection
Beyond the preview
Go deeper on Fecal microbiota transplant G3 capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal microbiota transplant G3 capsules.